MSDC-0602K improves liver enzymes, glycemic control in NASH with diabetes

BOSTON — Treatment with MSDC-0602K safely produced positive effects on glycemic control along with consistent improvement in liver enzymes and noninvasive hepatic markers in patients with nonalcoholic steatohepatitis and type 2 diabetes, according to data presented at The Liver Meeting 2019.
“When we talk about NASH, we talk about a disease that’s in the setting of overnutrition. Overnutrition can result in insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease and NASH, which frequently coexist,” Stephen A. Harrison, MD, medical director of Pinnacle

Source link

Related posts

Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats


Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis


The Strange Link Between Anti-TNFs and Psoriasis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World